News

Virginia Catalyst Awards $1.9 Million in Grants to Support Life Sciences in the Commonwealth

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC),  announced that it has awarded $1.9 million in grants to three life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 12 of Virginia Catalyst’s ongoing mission to stimulate economic development by promoting collaborative projects that address large, unmet needs for improving human health, and that can create high-paying jobs in the Commonwealth.

“We are excited to continue our mission of supporting collaborations and fostering economic growth in Virginia’s life sciences, enabling the Commonwealth to compete on a national and global scale,” said Mike Grisham, CEO, Virginia Catalyst. “The critical mass achieved by these collaborations provides Virginia with competitive advantages over other states and has resulted in significant outside capital being invested to finance the commercialization of Virginia’s innovations and create significant high-paying jobs for the Commonwealth.”

Through this 12th round of funding, Virginia Catalyst has awarded 49 grants totaling $24 million, resulting in over $44 million in matching funds and an additional $250 million in follow-on funding to date.

The awards, which range from $200,000 to $800,000, help fund collaborative efforts between industry and Virginia research universities with the goal of:

  • Funding innovative, collaborative, translational research projects that elevate the level of sponsored research at Virginia’s universities and have the potential to significantly improve human health and create high value jobs in the Commonwealth
  • Accelerating commercialization of Virginia research university inventions and discoveries and to achieve competitive critical mass through robust collaborations of Virginia research universities and industry

Grant Round 12 project awardees:

Project: Optimization and commercialization of environmentally-sustainable biofungicides

  • Company: AgroSpheres, Inc. (Charlottesville, VA)
  • University collaborators: Virginia Tech and University of Virginia
  • Funding amount: $600,000

Project: Design automation for scaled manufacturing of advanced custom orthopedic braces

  • Company: Icarus Medical Innovations (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Commonwealth University
  • Funding amount: $600,000

Project: Pilot study to evaluate a nonsurgical gel patch for eardrum repair in human patients

  • University collaborators: Eastern Virginia Medical School and Virginia Commonwealth University
  • Funding amount: $737,369

Recent News

07/30/2026

Governor Spanberger Announces $2.4 Million in Grants for Virginia’s Biomedical Innovation Ecosystem

Governor Abigail Spanberger today announced a $2.4 million investment in Virginia’s life sciences ecosystem through Virginia Catalyst’s highly competitive grant program. Virginia Catalyst was founded in 2013 as Virginia’s research consortium through the efforts of the Virginia General Assembly and five of Virginia’s premiere research institutions. These non-dilutive grants — funding that does not require

07/29/2026

Slone Partners Names Sona Stroud and Kim Wilson as Senior Partners

Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, today announced the appointments of Sona Stroud and Kim Wilson as Senior Partners. Stroud has been promoted to the role following nearly 15 years with the firm, while Wilson returns to the organization, further strengthening its leadership team with nearly 17 years

07/28/2026

NanOptical Biomedical Commercializes Cancer Imaging Technology

NanOptical Biomedical Inc., a biotechnology company working on next-generation contrast agents for photoacoustic imaging, has started operations at the Endeavor incubator in Innovation Park, Manassas. The company will manufacture SonoVanta™, a patent-pending contrast agent that improves the precision of cancer margin imaging, supporting more accurate biopsies and tumor removal. SonoVanta™ originated from research conducted at